Xeris Biopharma Holdings, Inc.
Precipitation resistant small molecule drug formulations
Last updated:
Abstract:
Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation. In certain aspects the formulations include at least one surfactant in a non-aqueous formulation, which prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into the systemic circulation.
Status:
Grant
Type:
Utility
Filling date:
31 May 2018
Issue date:
1 Jun 2021